Age, Biography and Wiki
John L. Wallace was born on 25 September, 1956 in Toronto, Ontario, Canada, is a John L. Wallace is medical scientist medical scientist. Discover John L. Wallace's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 67 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
67 years old |
| Zodiac Sign |
Libra |
| Born |
25 September 1956 |
| Birthday |
25 September |
| Birthplace |
Toronto, Ontario, Canada |
| Nationality |
Toronto, Ontario
|
We recommend you to check the complete list of Famous People born on 25 September.
He is a member of famous with the age 67 years old group.
John L. Wallace Height, Weight & Measurements
At 67 years old, John L. Wallace height not available right now. We will update John L. Wallace's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
John L. Wallace Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is John L. Wallace worth at the age of 67 years old? John L. Wallace’s income source is mostly from being a successful . He is from Toronto, Ontario. We have estimated John L. Wallace's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
|
John L. Wallace Social Network
Timeline
John L. Wallace (born September 25, 1956) is a medical scientist and was the founder of the Inflammation Research Network at The University of Calgary and inaugural director of the Farncombe Institute at McMaster University.
Since its inauguration in 1972, the Medal had been awarded twelve times; six of the recipients are Nobel Laureates.
From 1986 to 1989, he was an assistant professor at Queen's University.
From 1989 to 2009, Wallace was a professor of Pharmacology and Therapeutics at the University of Calgary, where he held the Canada Research Chair in Inflammation.
In 1989, he joined the University of Calgary, where he founded the Inflammation Research Network and held the Crohn's and Colitis Foundation of Canada Chair in Intestinal Disease Research.
Wallace co-founded NicOx in 1996, creating the first pharmaceutical company to commercialize gaseous mediator technology.
This board oversaw the development of nitric oxide-releasing NSAIDs.
He is also the founder of Antibe Therapeutics, which is developing a gaseous mediator drug development platform based on hydrogen sulfide.
In 2005, he acted as an invited expert for the US Food and Drug Administration's review of COX-2 inhibitors such as Vioxx.
Wallace graduated from Queen's University with his BSc and MSc and received his PhD from the University of Toronto.
He completed his post-doctoral studies under Dr. Brendan Whittle, Sir John Vane and Sir Salvador Moncada at Wellcome Research Laboratories in the UK.
Wallace received an MBA from the University of Birmingham (UK) in 2008.
Wallace is also the 2009 recipient of the Premier's Summit Award in Innovation, Canada's largest value research award (C$5 million) aimed at supporting the work of an individual scientist.
He is a fellow of the Royal Society of Canada, a member of the Brazilian Academy of Sciences, a fellow of the British Pharmacological Society, and a fellow and former president of the Canadian Association of Gastroenterology.
Wallace is an adjunct professor in the Faculty of Medicine at the University of Calgary, the Department of Pharmacology and Toxicology at the University of Toronto, and in the University Camilo Castelo Branco in São Paulo, Brazil.
He is Chief Scientific Officer of Antibe Therapeutics Inc., which he founded.
Antibe Therapeutics is based in Toronto, Ontario, Canada, and trades on the Toronto Stock Exchange (TSX:ATE).
John L. Wallace is a citizen of Canada, The Republic of Ireland and the United Kingdom.
Wallace's current research focuses on the mechanisms of internal injury induced by non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory drugs.
In parallel, Wallace has been investigating the factors that regulate and promote healing of ulcers.
He is also researching the causes of inflammatory bowel disease (Crohn's disease and ulcerative colitis).
Wallace's career has centred on the use of gaseous mediators to treat inflammation, particularly intestinal injury and dysfunction.
Wallace has published more than 500 peer-reviewed papers and is among the top 0.5 percent of biomedical scientists worldwide in citations (> 42,000), with a current Hirsch index of 110.
In November 2013, he became the tenth recipient of the Heymans Foundation Memorial Medal.
In 2014, Wallace co-founded the Inflammation Research Network of Canada.
